While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at ...

The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to ...

Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step ...

The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...

Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S.

A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...